Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT1A | P50416 | 7/20 | 0.50 |
| ▸ | CPT1B | Q92523 | 6/20 | 0.50 |
| ▸ | CPT2 | P23786 | 4/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | CASP7 | P55210 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 6/20 | 0.45 |
| ▸ | RAB9A | P51151 | 6/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.45 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2003474 | 0.85 | CPT1A (0.58) | CPT1ACPT1BCPT2CNR1CNR2 | |
| SCHEMBL2002607 | 0.84 | CNR1 (0.69) | CPT1ACPT1BCPT2CNR1CNR2 | |
| SCHEMBL2003576 | 0.83 | MAPT (0.51) | CPT1ACPT1BCPT2CNR1CNR2 | |
| SCHEMBL1995768 | 0.81 | NOTUM (0.53) | KDM4EALDH1A1ALOX15CASP1CASP7 | |
| SCHEMBL1999751 | 0.81 | CNR2 (0.71) | CPT1ACPT1BCPT2CNR1CNR2 | |
| SCHEMBL1996659 | 0.81 | MAPT (0.49) | CPT1ACPT1BCPT2CNR1CNR2 | |
| SCHEMBL2004423 | 0.78 | POLB (0.66) | KDM4EALDH1A1ALOX15HSD17B10MAPT | |
| SCHEMBL1999119 | 0.78 | MAPT (0.45) | KDM4EALDH1A1ALOX15CASP1CASP7 | |
| SCHEMBL1997340 | 0.78 | MAPT (0.48) | KDM4EALDH1A1ALOX15CASP1CASP7 | |
| SCHEMBL2001916 | 0.77 | RAB9A (0.47) | KDM4EALDH1A1ALOX15CASP1CASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960376-B2 | Benzo-fused heterocycles | CARA THERAPEUTICS, INC. (US) | 2011-06-14 | — | — | US | claimed |
| US-7960376-B2 | Benzo-fused heterocycles | CARA THERAPEUTICS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960376-B2 | Benzo-fused heterocycles | CARA THERAPEUTICS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960376-B2 | Benzo-fused heterocycles | CARA THERAPEUTICS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-20090075973-A1 | BENZO-FUSED HETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2009-03-19 | — | — | US | disclosed |
| US-20090075973-A1 | BENZO-FUSED HETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2009-03-19 | — | — | US | disclosed |
| US-20090075973-A1 | BENZO-FUSED HETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2009-03-19 | — | — | US | disclosed |
| WO-2009035997-A2 | BENZO-FUSED HETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075973-A1 | BENZO-FUSED HETEROCYCLES | CNR1, CNR2, TRPV1 | CPT1A 1957/4885CPT1B 4018/4885CPT2 3725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.